The American public's perennially low opinion of the pharmaceutical industry has gotten even lower, and it seems unlikely that public opinion will gain much ground over the next year.
The American public’s perennially low opinion of the pharmaceutical industry has gotten even lower. A new poll from Gallup revealed that just 35% of Americans have a positive view of the pharmaceutical industry, down from 40% in 2014. Meanwhile, the proportion with a negative view rose from 36% to 43%.
The rating for the pharmaceutical industry places it among the lowest-rated industry sectors. Others that received negative ratings include the legal field, the healthcare industry, the oil and gas industry, and, coming in dead last, the federal government.
“Prescription drug prices continue to rise in the US, driven partly by the introduction of specialty drugs that can cost as much as $150,000 annually,” Jim Norman wrote for Gallup. “With few indications that costs will stabilize soon, the issue has moved back onto the national political scene.”
The US has had a negative opinion of the pharmaceutical industry for a long time. Back in 1991, 73% of Americans said the cost of prescription drugs was an important reason for rising healthcare costs. And since Gallup started testing views of sectors in 2001, the pharmaceutical industry has only received overall positive views 3 times: 2001, 2003, and 2014. However, the industry has consistently ranked in the bottom third.
There are differences in opinion based on party affiliation. Over the last 2 years, Republicans have given the pharmaceutical industry a positive rating, while the Democrats rate it negatively. However, the difference shrinks when Gallup includes party leaners. In addition, many groups likely to support Democrats—such as nonwhites, people younger than 35 years, urban residents, and individuals with annual household incomes less than $50,000—have positive views of the pharmaceutical industry
The pharmaceutical industry will likely remain in the spotlight with Democratic president hopeful Bernie Sanders’ newly unveiled bill taking aim at prescription drug costs. The bill is in reaction to the fact that these drugs costs are so high, many Americans cannot afford them.
“The combination of constantly rising prices and a presidential campaign in which drug companies are under attack leaves little likelihood that the pharmaceutical industry will gain much ground in public opinion over the next year,” Norman concluded.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More